McClure, Mark E.
Gopaluni, Seerapani
Wason, James
Henderson, Robert B.
Van Maurik, Andre
Savage, Caroline C.O.
Pusey, Charles D.
Salama, Alan D.
Lyons, Paul A.
Lee, Jacinta
Mynard, Kim
Jayne, David R.
Jones, Rachel B.
,
Funding for this research was provided by:
Medical Research Centre (MR/R502145/1)
Article History
Received: 6 October 2022
Accepted: 3 March 2023
First Online: 11 March 2023
Declarations
:
: A favourable ethical opinion was granted by the National Research Ethics Service Committee East of England Cambridge Central reference number: 18/EE/0275. Informed consent has been obtained from all participants in this study.
: Not applicable for protocol design paper.
: The trial is funded through the GSK-MRC EMINENT programme. Belimumab (Benlysta) is marketed by GlaxoSmithKline (GSK). GSK has provided scientific expertise including advice on trial design, analysis and interpretation of the data and review of the manuscripts. MM is the COMBIVAS trial physician and MRC-GSK EMINENT fellow. RJ is the chief investigator for the study. She has received research funding from GSK, previously undertook an academic secondment to GSK 2011–2013, currently undertakes consultancy work for Chemocentryx and has an investigator-initiated study collaboration with Roche. DJ has received research grants from Roche/Genentech, Chemocentryx and Genzyme/Sanofi. PAL has received research funding from GSK. CP has consulted for Vifor and Alentis. JW has received research funding from Boehringer-Ingelheim and UCB. AvM, RH and CS are current or previous employees of GSK. The other authors declare that they have no competing interests.